A Multi-omics-based Metabolic Typing Study of Gastric Cancer

Sponsor

Zhejiang Cancer Hospital (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT06134011

Collaborator

(none)

480

Enrollment

Location

Anticipated Duration (Months)

39.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. The gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.

Condition or Disease	Intervention/Treatment	Phase
Gastric Cancer Multi-omics Diagnosis	Other: Without any intervention

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

480 participants

Observational Model:

Case-Only

Time Perspective:

Other

Official Title:

Clinical Study on Metabolic Typing of Gastric Cancer Based on Transcriptome, Metabolome and Other Multi-omics

Actual Study Start Date :

Sep 10, 2023

Anticipated Primary Completion Date :

Sep 10, 2024

Anticipated Study Completion Date :

Sep 10, 2024

Arms and Interventions

Arm	Intervention/Treatment
Cancer tissues	Other: Without any intervention There were no special interventions for the two groups.
Normal adjacent tissues	Other: Without any intervention There were no special interventions for the two groups.

Arm

Intervention/Treatment

Cancer tissues

Other: Without any intervention

There were no special interventions for the two groups.

Normal adjacent tissues

Other: Without any intervention

There were no special interventions for the two groups.

Outcome Measures

Primary Outcome Measures

The differences of the metabolism information [through study completion, an average of 6 months]
The differences of the metabolism information between gastric cancer tissues and non-cancerous gastric cancer tissues. These data included Metabolizing enzyme mRNA expression and metabolite content.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

18≤age≤80
Histologically or cytologically confirmed gastric cancer
Undergo surgery for radical or palliative gastric cancer (both open and laparoscopic)
Patients with survival follow-up information

Exclusion Criteria:

Two or more kinds of malignant tumors at the same time
Incomplete or missing case information
Preoperative diagnosis of residual gastric cancer

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)	Hangzhou	Zhejiang	China

Sponsors and Collaborators

Zhejiang Cancer Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Xiangdong Cheng, Secretary of the party committee, Zhejiang Cancer Hospital

ClinicalTrials.gov Identifier:

NCT06134011

Other Study ID Numbers:

IRB-2023-935

First Posted:

Nov 18, 2023

Last Update Posted:

Nov 18, 2023

Last Verified:

Nov 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Stomach Neoplasms

Study Results

No Results Posted as of Nov 18, 2023